GLP-1 vs Growth-Hormone Peptides: Different Goals, Different Evidence
Two peptide categories often lumped together — and the wildly different levels of proof behind each.
It’s easy to lump GLP-1 medications and growth-hormone peptides together. Both are peptide-based, both circulate in the same biohacking and clinic conversations, and both promise to reshape the body. But pull them apart and you find two categories with almost nothing in common — different goals, different mechanisms, and dramatically different amounts of evidence behind them.
GLP-1s: a well-mapped category
GLP-1 receptor agonists were developed and tested as drugs, the slow and expensive way — through large randomized trials with hard outcomes. The STEP 1 trial of once-weekly semaglutide 2.4 mg, published in NEJM in 2021, reported a mean weight reduction of about 14.9% at 68 weeks versus roughly 2.4% on placebo in adults with overweight or obesity. And the question that matters most for medicine — does it change events, not just numbers — has been tested too.
In SELECT (NEJM, 2023), 17,604 adults with established cardiovascular disease and overweight/obesity but without diabetes had a 20% lower risk of major adverse cardiovascular events on semaglutide (hazard ratio 0.80). That is the kind of evidence regulators and clinicians actually rely on.
That doesn’t make GLP-1s risk-free or right for everyone. But the foundation is solid, and the claims sit on real outcome data.
Growth-hormone peptides: a thinner foundation
The growth-hormone-stimulating peptides — secretagogues marketed for muscle, fat loss, recovery, and anti-aging — live in a very different evidence world. Much of their reputation rests on mechanism (they can raise growth hormone and IGF-1), small or older studies, and enthusiastic anecdote rather than large trials measuring outcomes people care about. Many are sold through unregulated channels, and their long-term safety in healthy adults is largely uncharacterized.
The contrast in short
| GLP-1 medications | GH peptides | |
|---|---|---|
| Evidence | Large RCTs, hard outcomes (STEP, SELECT) | Mostly mechanism + small studies |
| Regulation | Approved, defined indications | Often unregulated channels |
| Outcomes | Weight, glucose, cardiovascular events | Hormone levels; outcomes unproven |
| Long-term safety | Well-characterized | Largely unknown |
Raising a hormone level is not the same as improving health, and elevating growth-hormone signaling carries its own theoretical concerns over time. “Plausible mechanism” is where the GH-peptide story usually stops; for GLP-1s, the story continues into proven outcomes.
The takeaway
These two categories deserve to be judged separately. GLP-1 medications rest on robust, outcome-based evidence — substantial weight loss in STEP 1 and a 20% reduction in cardiovascular events in SELECT. Growth-hormone peptides rest mostly on mechanism and anecdote, with thin long-term safety data. Sharing the word “peptide” doesn’t make them equivalent — and treating them as interchangeable is exactly the kind of shortcut that leads people astray.